The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
April 18th 2024
A new study found an intervention targeting proton pump inhibitor overuse was linked to an absolute reduction of 7.3%.
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Rapid Oncology Abstract Review®: Key Updates in Gastrointestinal Cancers from the ASCO Annual Meeting
View More
Medical Crossfire®: Bridging Precision Medicine Techniques and Emerging Treatments in Metastatic Colorectal Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Burst CME: Incorporating the Latest Updates in IBS Treatment into Your Practice
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Oncology Town Hall: Live Report from Barcelona for Advances in the Treatment of GI Cancers
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 20th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Working Group: Streamlining the Pathway from Diagnosis to Treatment in Inflammatory Bowel Disease
View More
Advances In™: The Evolving Role of VEGFR in the Treatment of Refractory mCRC
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Investigators Identify Risk Factors for HBV, HCV Among Pregnant Women
There were several risk factors identified, including abortion, hospitalization, past surgical procedure, dental extraction, delivery in hospital, injection in hospitals, and household contact with jaundice.
Diversity and Composition of Gut Microbiota Vary Between Healthy Individuals and HBV Patients
A beta diversity analyses revealed a distinct clustering pattern between healthy controls and patients with HBV-related liver disease and the composition of bacteria from the phylum level to the genus level varies across the stages of liver disease.
Individuals who sought outpatient mental health and addiction services were generally younger, proportionately more female, more likely to have a psychiatric comorbidity, and more likely to have had their index alcohol-related hospitalization attributed to than to other diagnoses such as harmful alcohol use or alcoholic liver disease.
Claire Jansson-Knodell, MD: Treating Pregnant Women With Celiac Disease
Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.
Jessica Allegretti, MD, MPH: An Update on the Quasar Study at DDW 2023
In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.